Collectively, this study suggested that NSC765598 has a potential for multi-target inhibition of EGFR/iNOS/mTOR/TGFB1/FGFR/MAP2K1 and could serve as a lead compound for developing new therapeutics for cancer treatment. The gene discussed is NOS2; the disease is cancer.